US2011104819A1PendingUtilityA1

Modification of Bioassays for Detection of Antigens Characteristic of Bacteria that are Causative of Ear and Respiratory Infections to Eliminate False Positive Results Caused by Nasopharyngeal Colonization of Children

Individually held — no corporate assignee on recordPriority: Feb 27, 2002Filed: Apr 1, 2010Published: May 5, 2011
Est. expiryFeb 27, 2022(expired)· nominal 20-yr term from priority
G01N 33/54388G01N 33/56911
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to modifying rapid immunochromatographic (“ICT”) tests for the detection of characteristic carbohydrate antigens of bacteria that are known to be causative of otitis media and respiratory diseases in children under the age of approximately 12 years. Children of this age group are also prone to nasopharyngeal colonization with the same bacteria, and urine samples taken from colonized, but otherwise healthy, children were shown to exhibit an unduly high incidence of test results that were false positive for the presence of disease. The test modifications, which maintain the test sensitivity unchanged and the test specificity at a value above 90% were developed to insure that healthy, albeit colonized, children were not medicated for disease the bacteria are known to cause. The modifications involve either (1) reducing the total amount of antibodies to the carbohydrate antigen employed in each test, (2) adding at least one fixed “scrub” line located just prior to the capture line in the sample flow path to the preprepared ICT test strip to “scrub” out an identical amount of target antigen from all bodily fluid test samples obtained from both colonized but otherwise healthy children and diseased children, or (3) combinations of (1) and (2).

Claims

exact text as granted — not AI-modified
1 . In a bioassay for the detection in bodily fluids of teenage and adult humans of an antigen that is characteristic of a kind of bacteria causative of human ear and respiratory tract infections, which kind of bacteria also frequently colonizes the nasopharynx areas of children up to the age of about 12 years without infecting them,
 the improvement in said bioassay for detection of said antigen in bodily fluid samples from said children up to the age of about 12 years which at least substantially reduces the incidence of false positive results stemming from nasopharyngeal colonization of otherwise healthy children, while maintaining the sensitivity of said bioassay to the presence of said antigen stemming from an infection and also maintaining the specificity of said bioassay at not less than 90%,   which improvement consists in reducing the total amount of antibodies to said antigen that are employed in each bioassay to a total amount less than that utilized in the otherwise identical bioassay employed in testing bodily fluids of teenage and adult humans, wherein the amount of reduction of total antibodies needed to obtain the stated results has been determined empirically in bioassay tests, wherein the total amount of antibodies present per test are varied, and the tests representing each variation are run identically on samples of bodily fluids taken from each of (1) otherwise healthy children known to have nasopharyngeal colonization by the bacteria of which the antigen is characteristic and (2) children known to have an ear or pneumococcal infection caused by the kind of bacteria of which the antigen is characteristic.   
     
     
         2 . The improvement according to  claim 1  wherein the antigen is characteristic of a kind of bacteria selected from among  Streptococcus pneumoniae,  nontypable  Haemophilus influenzae, Moraxella catarrhalis,  and  Staphylococcus aureus.    
     
     
         3 . The improvement according to  claim 2  wherein the antigen is a carbohydrate antigen characteristic of one of these bacteria. 
     
     
         4 . The improvement according to  claim 3  wherein the antigen is the polysaccharide antigen common to all serotypes of  Streptococcus pneumoniae,  and the kind of bacteria is  Streptococcus pneumoniae.    
     
     
         5 . The improvement according to  claim 1  wherein the bioassay is an immunochromatographic assay. 
     
     
         6 . The improvement according to  claim 5  where the antibodies in each test are in part conjugated to a tag, in movable form, and in part immovably fixed on a capture line where tagged antibody-antigen-fixed antibody “sandwiches” form and mass at the conclusion of the bioassay. 
     
     
         7 . The improvement according to  claim 6  wherein the antibodies are antibodies to the polysaccharide antigen common to all serotypes of  Streptococcus pneumoniae  and the kind of bacteria is  Streptococcus pneumoniae.    
     
     
         8 . The improvement according to  claim 6  wherein the amount of reduction of total antibodies needed to achieve the stated results has been empirically determined to be that attained (1) by conjugating a part of the antibodies to colloidal gold and making a conjugate solution having an optical density of 1.5 and (2) the concentration of antibody immovably fixed to the capture line is placed there from a solution containing 0.3 mg./ml. of antibody delivered at a rate of 0.5 ml. per 6 mm. of substrate by the delivery tip of a precision pump. 
     
     
         9 . In an immunochromatographic (“ICT”) bioassay for the detection in bodily fluids of teenage and adult humans of an antigen that is characteristic of a kind of bacteria causative of human ear and respiratory tract infections, which kind of bacteria also frequently colonizes the nasopharynx areas of children up to the age of about 12 years without infecting them,
 the improvement in said biassay for detection of said antigen in bodily fluid samples from said children up to the age of about 12 years which at least substantially reduces the incidence of false positive results stemming from nasopharyngeal colonization of otherwise healthy children, while maintaining the sensitivity of said bioassay to the presence in bodily fluids of said antigen stemming from an infection and also maintaining the specificity of said bioassay at not less than 90%, 
 which improvement consists in adding at least one immovable “scrub” line located just prior to the capture line in the sample flow path of the ICT test strip to remove excess antigen by “scrubbing” out an identical portion thereof from samples of bodily fluid of each of (a) uninfected children who are colonized nasopharyngeally by the bacteria of which the antigen is characteristic and (b) persons who are infected by the same bacteria, wherein the number of capture lines, the concentration of antibody deposited on each capture line and the extent to which the concentration of antibodies otherwise employed in the test is modified, if at all, in order to obtain the stated results, have been determined empirically in bioassay tests wherein the number of “scrub” lines and the concentration of antibody on each “scrub” line and the concentration of antibodies otherwise present per test are varied and tests representing each variation are run identically on samples of bodily fluids taken from each of (1) otherwise healthy children known to have nasopharyngeal colonization by the bacteria of which the antigen is characteristic and (2) children known to have an ear or pneumococcal infection caused by the kind of bacteria of which the antigen is characteristic.

Join the waitlist — get patent alerts

Track US2011104819A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.